Weight Watchers went bankrupt in May, but now it promises it's trimmed the fat off its books and is ready to rejoin the ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

The actor is raising awareness of clinical trials for cancer in partnership with “GMA” sponsor Eli Lilly & Co.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

Tauranga locals aren’t fussed Jaffas are gone — the iconic orange chocolate balls were mostly just for movie nights and ...

The Matrix co-director calls the film a “fever dream reflecting on assimilation and the investigation of trans identity.” ...

I was just a baby scientist when I discovered the hormone that made Ozempic possible. I had no idea how life-changing—and ...

MCU's Quantumania stars Evangeline Lilly and Michael Douglas recently confirmed that they would be taking a step back from ...

Eli Lilly made a move that could help address a drawback of its anti-obesity medicines. This could help it fend off mounting competition in this fast-growing area. Lilly's business extends far ...

Abbott Laboratories is a dividend growth machine that's known for consistency. AbbVie's dividend has more than quadrupled ...

Eli Lilly impressed analysts with results that point to the potential for the drug candidate to form part of a market-leading Zepbound combination.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...